Literature DB >> 31090136

Molecular pathways regulated by areca nut in the etiopathogenesis of oral submucous fibrosis.

Paturu Kondaiah1, Ila Pant2, Imran Khan3.   

Abstract

Many oral mucosal lesions are due to substance abuse, such as tobacco and areca nut, amongst others. There is considerable evidence that oral lesions/disorders such as some leukoplakias, most erythroplakias, and submucous fibrosis have malignant potential, with a conversion rate of 5%-10% over a 10-year period. There have been several reports on possible biomarkers that predict malignant conversion of the oral lesions associated with these disorders. Management of these is mostly surgical removal of the lesion followed by observation, and in some cases treatment by antioxidants and anti-inflammatory agents. Oral submucous fibrosis is due to excessive deposition of extracellular matrix in the connective tissue plus, particularly, collagens. The deposition of collagen leads to stiffness of the affected regions and results in difficulty in mouth opening. Areca nut chewing is proposed as the most probable etiological factor in the manifestation of oral submucous fibrosis. Several studies suggest involvement of proinflammatory cytokines, dysregulated by areca nut, in the development of the disease. Amongst these, transforming growth factor-β is in the forefront, which is also shown to be involved in fibrosis of other organs. This review addresses the molecular mechanisms involved in oral submucous fibrosis development and provides a model for the regulation of transforming growth factor-β by areca nut. It provides an exemplar of the role of modern molecular techniques in the study of oral disease.
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2019        PMID: 31090136     DOI: 10.1111/prd.12266

Source DB:  PubMed          Journal:  Periodontol 2000        ISSN: 0906-6713            Impact factor:   7.589


  5 in total

1.  [Efficacy of curcumin in the treatment of oral submucous fibrosis: a Meta-analysis].

Authors:  Jin-Cai Guo; Hui Xie; Hao Wu; Tie-Jun Tong
Journal:  Hua Xi Kou Qiang Yi Xue Za Zhi       Date:  2021-04-01

2.  The study of placentrex and hydrocortisone as an adjunct treatment in oral submucous fibrosis.

Authors:  Parag Kisave; Vijay Shekhar; Prasoon S Babu; Syed W U Hussaini; Rishabh Bhanot; Abhinav Kumar; Rahul V C Tiwari
Journal:  J Family Med Prim Care       Date:  2020-05-31

3.  The Role of Increased Connective Tissue Growth Factor in the Pathogenesis of Oral Submucous Fibrosis and its Malignant Transformation-An Immunohistochemical Study.

Authors:  Aakruti Mahendra Shah; Kejal Jain; Rajiv S Desai; Shivani Bansal; Pankaj Shirsat; Pooja Prasad; Kshitija Bodhankar
Journal:  Head Neck Pathol       Date:  2021-02-05

4.  Adipose-Derived Stem Cell-Derived Extracellular Vesicles Inhibit the Fibrosis of Fibrotic Buccal Mucosal Fibroblasts via the MicroRNA-375/FOXF1 Axis.

Authors:  Bin Han; Yanhui Zhang; Yuxia Xiao; Bohong Shi; Hong Wu; Desheng Liu
Journal:  Stem Cells Int       Date:  2021-06-22       Impact factor: 5.443

Review 5.  Genetic Susceptibility and Protein Expression of Extracellular Matrix Turnover-Related Genes in Oral Submucous Fibrosis.

Authors:  Ru-Hsiu Cheng; Yi-Ping Wang; Julia Yu-Fong Chang; Yu-Hwa Pan; Mei-Chi Chang; Jiiang-Huei Jeng
Journal:  Int J Mol Sci       Date:  2020-10-30       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.